Background and Aims: This real-world study aimed to assess the effectiveness and safety of vildagliptin plus metformin (VM) vs. other oral dual antidiabetes agents (OD) in type 2 diabetes mellitus (T2DM) patients in China.

Materials and Methods: This prospective, 1-year, real-world study was conducted in 52 sites in patients inadequately controlled by monotherapy. Eligible patients were assigned either vildagliptin dual therapy or other OD according to local physician’s decision. The primary outcome was the proportion of patients with HbA1c<7%, without tolerability events (hypoglycemia, weight gain, or discontinuation due to gastrointestinal event) at 12th month. Secondary outcomes included subgroup analysis and tolerability.

Results: Totally 604 patients received VM and 670 patients received OD. After propensity score-matched, baseline HbA1c and BMI were similar in both groups. After 12-month treatment, 55.4% patients in VM and 36.2% in OD reached primary outcome (P<0.001; OR, 1.88; 95% CI 1.47-2.40). In all subgroups, VM significantly benefited the primary outcome (Figure 1). Numerically, less tolerability events occurred in VM vs. OD (5.8% vs. 14.8%).

Conclusion: China PDS demonstrates that in a real-life setting, vildagliptin plus metformin is effective in glycemic control and is well tolerated.
graphic
View largeDownload slide
Disclosure

Y. Han: None. L. Chen: None. D. Hu: None. H. Jin: None. N. Yang: None. X. Shi: None. Q. Li: None. L. Liang: None. L. Zang: None. M. Liu: None. J. He: None. Y. Mu: None.

© 2018 by the American Diabetes Association.
2018
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.